Patents by Inventor Farid Ahmed

Farid Ahmed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11325885
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: May 10, 2022
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
  • Patent number: 11312680
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: April 26, 2022
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
  • Publication number: 20220062264
    Abstract: Stroke patients with comorbidities, such as diabetes, hypertension, or other conditions associated with cardiovascular, pulmonary or renal disease do not respond well to current treatments for stroke. An inhibitor of S-nitrosoglutathione reductase (GSNOR) is administered as an adjunct therapy with remote ischemic conditioning (RIC) to treat a stroke in a subject having at least one comorbidity, such as diabetes and hypertension. When performed in conjunction with GRI therapy and RIC, intravenous tissue plasminogen activator therapy (IVT) for thrombolysis and/or endovascular thrombectomy (EVT) for clot retrieval are effective in subjects with comorbidities, even after five hours post-onset of stroke.
    Type: Application
    Filed: July 13, 2021
    Publication date: March 3, 2022
    Inventors: Syed Kashif ZAIDI, Md. Nasrul HODA, Muhammad Hussain AL-QAHTANI, Farid Ahmed, Heba Al Khatabi
  • Patent number: 11246861
    Abstract: Stroke patients with comorbidities, such as diabetes, hypertension, or other conditions associated with cardiovascular, pulmonary or renal disease do not respond well to current treatments for stroke. An inhibitor of S-nitrosoglutathione reductase (GSNOR) is administered as an adjunct therapy with remote ischemic conditioning (RIC) to treat a stroke in a subject having at least one comorbidity, such as diabetes and hypertension. When performed in conjunction with GRI therapy and RIC, intravenous tissue plasminogen activator therapy (IVT) for thrombolysis and/or endovascular thrombectomy (EVT) for clot retrieval are effective in subjects with comorbidities, even after five hours post-onset of stroke.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: February 15, 2022
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Syed Kashif Zaidi, Md. Nasrul Hoda, Muhammad Hussain Al-Qahtani, Farid Ahmed, Heba Al Khatabi
  • Patent number: 11220485
    Abstract: Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: January 11, 2022
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Ahmed Esmat, Farid Ahmed, Azizah M. Malebari, Ashraf B. Abdel-Naim, Thikryat Neamatallah
  • Patent number: 11214537
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: January 4, 2022
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
  • Publication number: 20210395187
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Application
    Filed: August 19, 2021
    Publication date: December 23, 2021
    Applicant: King Abdulaziz University
    Inventors: Moustafa E. EL-ARABY, Abdelsattar M. OMAR, Maan T. KHAYAT, Dhaval SHAH, Martin K. SAFO, Azizah M. MALEBARI, Farid AHMED
  • Publication number: 20210380526
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Application
    Filed: August 19, 2021
    Publication date: December 9, 2021
    Applicant: King Abdulaziz University
    Inventors: Moustafa E. EL-ARABY, Abdelsattar M. OMAR, Maan T. KHAYAT, Dhaval SHAH, Martin K. SAFO, Azizah M. MALEBARI, Farid AHMED
  • Patent number: 11180458
    Abstract: Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: November 23, 2021
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Ahmed Esmat, Farid Ahmed, Azizah M. Malebari, Ashraf B. Abdel-Naim, Thikryat Neamatallah
  • Patent number: 11174233
    Abstract: Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: November 16, 2021
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Ahmed Esmat, Farid Ahmed, Azizah M. Malebari, Ashraf B. Abdel-Naim, Thikryat Neamatallah
  • Publication number: 20210340110
    Abstract: Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 4, 2021
    Applicant: King Abdulaziz University
    Inventors: Moustafa E. EL-ARABY, Abdelsattar M. Omar, Ahmed Esmat, Farid Ahmed, Azizah M. Malebari, Ashraf B. Abdel-Naim, Thikryat Neamatallah
  • Publication number: 20210340097
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 4, 2021
    Applicant: King Abdulaziz University
    Inventors: Moustafa E. EL-ARABY, Abdelsattar M. OMAR, Maan T. KHAYAT, Dhaval SHAH, Martin K. SAFO, Azizah M. MALEBARI, Farid AHMED
  • Patent number: 11142493
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: October 12, 2021
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
  • Patent number: 11136288
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: October 5, 2021
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
  • Publication number: 20210188765
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Application
    Filed: March 4, 2021
    Publication date: June 24, 2021
    Applicant: King Abdulaziz University
    Inventors: Moustafa E. EL-ARABY, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
  • Publication number: 20210139434
    Abstract: Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Application
    Filed: November 12, 2019
    Publication date: May 13, 2021
    Applicant: King Abdulaziz University
    Inventors: Moustafa E. EL-ARABY, Abdelsattar M. OMAR, Ahmed ESMAT, Farid AHMED, Azizah M. MALEBARI, Ashraf B. ABDEL-NAIM, Thikryat NEAMATALLAH
  • Patent number: 10988439
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: April 27, 2021
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
  • Publication number: 20200385337
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Application
    Filed: August 6, 2020
    Publication date: December 10, 2020
    Applicant: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
  • Publication number: 20200385336
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Application
    Filed: June 4, 2019
    Publication date: December 10, 2020
    Applicant: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
  • Patent number: 10844007
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: November 24, 2020
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed